reports
- Jonathan Moreland
ZEUS OLYMPIC STEEL INC.
XOMA XOMA
NWBI NORTHWEST BANCSHARES INC.
NRIM NORTHRIM BANCORP INC.
MERC MERCER INTERNATIONAL INC.
MCY MERCURY GENERAL CORPORATION
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
CRM SALESFORCE.COM INC.
CE CELANESE CORPORATION
ARE ALEXANDRIA REAL ESTATE EQUITIES INC.
APLE APPLE HOSPITALITY REIT INC
AMH AMERICAN HOMES 4 RENT CLASS A
MGM MGM RESORTS INTERNATIONAL
OXM OXFORD INDUSTRIES INC.
RSG REPUBLIC SERVICES INC.
MHH MASTECH DIGITAL
WMG WARNER MUSIC GROUP CORP.
NHF NEXPOINT CREDIT STRATEGIES FUN
PMTS CPI CARD GROUP
NWPP NEW PEOPLES BANKSHARES INC.
MIDD THE MIDDLEBY CORPORATION
AVTR AVANTOR
SELF INC.
ALTG SELF STORAGE GROUP
IMVT INC.
ORIC ALTA EQUIPMENT GROUP INC.
NOG IMMUNOVANT INC
MRVI ORIC PHARMACEUTICALS
DMAC NORTHERN OIL AND GAS
AMR MARAVAI LIFESCIENCES HOLDINGS
NRDY DIAMEDICA THERAPEUTICS INC.
ABSI ALPHA METALLURGICAL RESOURCES INC
IMMX NERDY INC.
LUCY ABSCI CORP
LIN IMMIX BIOPHARMA INC
MNR INNOVATIVE EYEWEAR INC
XELB LINDE PUBLIC LIMITED COMPANY
FEAM MACH NATURAL RESOURCES LP
SEVN XCEL BRANDS INC.
5E ADVANCED MATERIALS INC.
SEVEN HILLS REALTY TRUST
Lexicon Pharmaceuticals Announces Publication of Preclinical Data in t...
Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851 THE WOODLANDS, Texas, Dec. 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced the publication of preclinical data validating Acyl-CoA Synthetase 5 (ACSL5) as a target for obesity and chronic weight management. The paper, titled “Acyl-CoA Synthetase 5 knockout and inhibitors protect against diet-induced obesity in mice by activating the ileal brake,” was published online in the . ACSL5 is an enz...
- Jonathan Moreland
NWBI NORTHWEST BANCSHARES INC.
MMLP MARTIN MIDSTREAM PARTNERS L.P.
DIN DINE BRANDS GLOBAL INC.
CRM SALESFORCE.COM INC.
CBRL CRACKER BARREL OLD COUNTRY STORE INC.
TZOO TRAVELZOO
NHF NEXPOINT CREDIT STRATEGIES FUN
DMAC DIAMEDICA THERAPEUTICS INC.
ZIP ZIPRECRUITER
NRDY INC.
LIN NERDY INC.
MXF LINDE PUBLIC LIMITED COMPANY
MDRR THE MEXICO FUND
GF INC.
CBIO MEDALIST DIVERSIFIED REIT INC.
SINT THE NEW GERMANY FUND
GMRE INC.
SEVN CRESCENT BIOPHARMA INC.
SINTX TECHNOLOGIES INC.
GLOBAL MEDICAL REIT INC.
SEVEN HILLS REALTY TRUST
Clinical Data on Effect of Sotagliflozin on Adipose Distribution in No...
Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum THE WOODLANDS, Texas, Dec. 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) announced clinical data on adipose tissue distribution in non-diabetic patients treated with sotagliflozin will be presented at the 22nd Global Cardio Vascular Clinical Trialists Forum (CVCT 2025). The conference is being held December 8-10, 2025, at the Mayflower Hotel in Washington, D.C. This data is from SOTA-P-CARDIA, a prospective, randomized, double-...
Lexicon Pharmaceuticals to Participate in Two Upcoming December Invest...
Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences THE WOODLANDS, Texas, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3 at 9:00 a.m. ET and at the 8th Annual Evercore Healthcare Conference on Thursday, December 4 at 9:10 a.m. ET. The live events and replays of the presentations can be accessed via the Events page of the Company’s website at . About Lexicon Pharmaceutic...
Moody's Ratings announces completion of a periodic review of ratings o...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of BlackRock MuniYield Pennsylvania Quality Fund and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 17 November 2025 in which we reassessed the appropriateness o...
SiriusPoint announces Maria Tarhanidis as Chief Investment Officer
SiriusPoint announces Maria Tarhanidis as Chief Investment Officer HAMILTON, Bermuda, Nov. 18, 2025 (GLOBE NEWSWIRE) -- SiriusPoint Ltd. (“SiriusPoint” or the “Company”) (NYSE: SPNT), a global specialty insurer and reinsurer, has today announced the appointment of Maria Tarhanidis as Chief Investment Officer, effective December 2, 2025. Based in New York, Ms. Tarhanidis will join the senior leadership team and will report to Jim McKinney, Chief Financial Officer. In her role, she will be responsible for overseeing strategic asset allocation, investment performance, and portfolio risk man...
Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London He...
Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference THE WOODLANDS, Texas, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Jefferies 2025 London Healthcare Conference on Tuesday, November 18 at 5:00 p.m. GMT (12:00 p.m. EST). The live events and replays of the presentations can be accessed via the Events page of the Company’s website at . About Lexicon Pharmaceuticals Lexicon is a biopharmaceutical company with a mission of pioneering med...
Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Eje...
Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025 Oral presentation highlights sotagliflozin's unique benefits to HFpEF patients in significantly improving cardiac and physical performance, and quality of life THE WOODLANDS, Texas, Nov. 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced that new sotagliflozin clinical data was presented at the AHA Annual Scientific Sessions 2025. The data highlighted benefits observed from sot...
Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results a...
Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates FDA End-of-Phase 2 meeting for pilavapadin in DPNP to be held by year-end All IND-enabling studies of LX9851 for obesity completed and submitted to licensee Novo Nordisk Site initiation for SONATA-HCM Phase 3 study of sotagliflozin in both obstructive and non-obstructive HCM completed; enrollment completion on target for 2026 Additional data in support of potential resubmission of Zynquista for type 1 diabetes submitted to FDA Conference call and webcast at 8:30 am ET THE WOODLANDS, Texas,...
Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient...
Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association’s Sessions 2025 in New Orleans Study results further differentiate sotagliflozin from SGLT inhibitors and cardiac myosin inhibitors THE WOODLANDS, Texas, Nov. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced that data from three studies of sotagliflozin will be presented during upcoming medical meetings. Two studies will be presented at the American Heart Association’s (AHA) Scientific Sessions 2025, b...
SiriusPoint Reports Third Quarter 2025 Results with Core Combined Rati...
SiriusPoint Reports Third Quarter 2025 Results with Core Combined Ratio of 89.1% HAMILTON, Bermuda, Oct. 30, 2025 (GLOBE NEWSWIRE) -- SiriusPoint Ltd. (“SiriusPoint” or the “Company”) (NYSE:SPNT) today announced results for its third quarter ended September 30, 2025 Combined ratio of 89.1% in the third quarter for Core business with underwriting income up 11% to $70 millionThird quarter return on equity of 17.7%, with operating return on equity of 17.9% in the quarter contributing to year to date operating return on equity of 16.1%, both exceeding our 12-15% ‘across the cycle’ target ran...
SiriusPoint Announces Dividend on Series B Preference Shares
SiriusPoint Announces Dividend on Series B Preference Shares HAMILTON, Bermuda, Oct. 30, 2025 (GLOBE NEWSWIRE) -- SiriusPoint Ltd. (“SiriusPoint” or the “Company”) (NYSE: SPNT), an international specialty insurer and reinsurer, has announced that the Audit Committee of the Board of Directors of SiriusPoint Ltd. approved a quarterly cash dividend of $0.50 per share on its 8.00% Resettable Fixed Rate Preference Shares, Series B, $0.10 par value, $25.00 liquidation preference per share payable on or prior to November 28, 2025 to Series B shareholders of record as of November 13, 2025. About...
Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results...
Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025 THE WOODLANDS, Texas, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its third quarter 2025 financial results on Thursday, November 6, 2025, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the conference call live via webcast on the Events page of the Company’s webs...
- Jonathan Moreland
ASA ASA
NSC NORFOLK SOUTHERN CORPORATION
RVP RETRACTABLE TECHNOLOGIES INC.
RMCF ROCKY MOUNTAIN CHOCOLATE FACTORY INC.
NWFL NORWOOD FINANCIAL CORP.
BWB BRIDGEWATER BANCSHARES
RYES PATRIOT MINEFINDERS INC.
BHRB BURKE & HERBERT BANK & TR/VA
EBC EASTERN BANKSHARES INC
VANI VIVANI MEDICAL INC
GF THE NEW GERMANY FUND
INC.
SiriusPoint Announces Will Nihan as IMG CEO
SiriusPoint Announces Will Nihan as IMG CEO HAMILTON, Bermuda, Oct. 21, 2025 (GLOBE NEWSWIRE) -- SiriusPoint Ltd. (“SiriusPoint”) (NYSE: SPNT), a global specialty insurer and reinsurer, has today announced the appointment of Will Nihan as Chief Executive Officer at International Medical Group (“IMG”). IMG is SiriusPoint’s wholly owned subsidiary and a leader in global insurance benefits and assistance services. Mr. Nihan joins IMG on 3 November 2025 from Travelex Insurance Services, where he was President and CEO. In his role at Travelex, Mr. Nihan drove top line growth, improved profita...
SiriusPoint Announces Date for Third Quarter 2025 Earnings Release
SiriusPoint Announces Date for Third Quarter 2025 Earnings Release HAMILTON, Bermuda, Oct. 16, 2025 (GLOBE NEWSWIRE) -- SiriusPoint Ltd. (NYSE: SPNT) (“SiriusPoint” or the “Company”) today announced that it is planning to release its third quarter 2025 financial results after the market close on Thursday, October 30, 2025. The Company will also hold a conference call, including a question-and-answer session, to discuss its financial results at 8:30 am (Eastern Time) on Friday, October 31, 2025. The webcast of the live conference call can be accessed by logging onto the Investor Relations...
Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabet...
Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit – Results support advancement of 10 mg dose into Phase 3 development – – End-of-Phase 2 meeting request accepted by U.S. FDA; partnership discussions progressing – THE WOODLANDS, Texas, Oct. 14, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced the Company presented additional clinical data and program updates from its Phase 2 pilavapadin program at the 19th Annual Pain Therapeutics Summit. These data follow the from the Phase 2b PROGRESS ...
Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy G...
Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain Diverse group of stakeholders aligned around the importance of elevating public awareness of need for new treatments for chronic pain and the need to expand the Alternatives to PAIN Act THE WOODLANDS, Texas, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Yesterday, (Nasdaq: LXRX) hosted and participated in a roundtable discussion with experts to explore how to enhance current and future legislative and policy efforts to better meet the needs of Americans suffering from chronic pain. The perspectiv...
SiriusPoint Announces Sale of Arcadian MGA for $139m with Long Term Ca...
SiriusPoint Announces Sale of Arcadian MGA for $139m with Long Term Capacity Deal Until 2031 HAMILTON, Bermuda, Oct. 06, 2025 (GLOBE NEWSWIRE) -- SiriusPoint Ltd. (“SiriusPoint”) (NYSE: SPNT), a global specialty insurer and reinsurer, has today announced its agreement to sell its 49% equity stake in managing general agent, Arcadian Risk Capital (“Arcadian”) to Lee Equity Partners for total consideration of $139 million, inclusive of a pre-close dividend. SiriusPoint has also renewed and extended its capacity agreement with Arcadian until the end of 2031. Upon completion of the sale, Siri...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.